Annual reports confirm sequencing-related drug-development solutions for pharmaceutical companies. The current website offers preclinical, translational, organoid drug-sensitivity, and multiomics services. Much business serves academic research; included as diversified with group-level financials.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY PRC Accounting Standards / consolidated
2,209,635,175.63
166,947,178.08 Net income attributable to shareholders of the listed company
Consolidated group totals include diagnostic, research and other products/services; they are not CRO or central laboratory segment revenue.
Key accounting data appear on PDF page 9 of the 2025 annual report. Research sequencing is the group’s principal business; drug R&D services do not represent all revenue.
2026Q3 (YTD) · Reporting notes
Consolidated group totals include diagnostic, research and other products/services; they are not CRO or central laboratory segment revenue.
Latest figures cover January–September 2026 year to date, not the third quarter alone; checked against the original quarterly and consolidated cash flow statements.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The 2026 website describes an end-to-end offering in organoid generation, characterization, drug-sensitivity testing, and multiomics. The 2025 annual report identifies pharmaceutical companies as commercial customers.
SSE:688315; the 2025 annual report and latest 2026 report were read from original consolidated statements.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.
